Hypertrophic cardiomyopathy (HCM) is believed to affect approximately 1 in every 500 individuals. While it can manifest at any age, it typically arises during adolescence or early adulthood. Mortality rates in HCM are lower than initially anticipated, particularly among treated patients, although they still exceed those of the general population. While the majority of HCM patients experience few or no symptoms, a notable minority will progress to advanced heart failure, atrial fibrillation, or stroke. Adverse outcomes have been linked to factors such as the presence of left ventricular outflow tract obstruction, atrial fibrillation, the onset of systolic dysfunction (known as end-stage HCM), and potentially the development of apical aneurysms.